N-Methylolacrylamide

101.10400

101.10

213-103-2

W8W68JL80Q

1637

553

DTXSID3020885

2924199090

49.33000

-0.37070

N-methylolacrylamide appears as a colorless or yellow aqueous solution.

1.074

74.5 °C

318.1ºC at 760mmHg

146.2ºC

n20/D 1.413

Solubility in water, g/100ml at 20°C: 188

Refrigerator

Vapour pressure, Pa at 25°C: 0.03 (negligible)

Soluble in water.

Alcohols and Polyols

Polymerizable

N-METHYLOLACRYLAMIDE may be sensitive to prolonged exposure to light. Polymerization and generation of heat and flames may occur on exposure to to heat or contaminants. Incompatible with strong oxidizers. (NTP, 1992)

UN 2810

3

R22

26

AS3600000

Xn

Separated from acids. Store only if stabilized. Store in an area without drain or sewer access.

May undergo spontaneous combustion in storage.

P201-P280-P301 + P310 + P330-P333 + P313

H301-H317-H340-H350-H361-H372

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Excessive heat, smoke, flames, and cracking noise were emitted from stored fibre drums of the monomer, some unopened. Polymerization may have been initiated by minor contaminants (perhaps as vapors), and/or by excessively warm storage conditions.

DHHS/NTP; Toxicology & Carcinogenesis Studies of N-Methyloacrylamide in F344/N Rats and B6C3F1 Mice (Gavage Studies) Technical Report Series No. 352 (1989) NIH Publication No. 89-2807

Literature sources indicate that this chemical is nonflammable. (NTP, 1992)|Combustible.

|Danger|H301 (38.22%): Toxic if swallowed [Danger Acute toxicity, oral]|P201, P202, P260, P261, P264, P270, P272, P273, P280, P281, P301+P310, P302+P352, P305+P351+P338, P308+P313, P314, P321, P330, P332+P313, P333+P313, P337+P313, P362, P363, P405, and P501|Aggregated GHS information provided by 524 companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H302: Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P260, P261, P264, P270, P271, P272, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P314, P321, P330, P332+P313, P333+P313, P337+P313, P362, P363, P403+P233, P405, and P501|P201, P202, P260, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P309+P311, P314, P330, P337+P313, P405, and P501

Fires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)|Use water spray, powder, alcohol-resistant foam, carbon dioxide. In case of fire: keep drums, etc., cool by spraying with water.

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned. STORAGE PRECAUTIONS: You should protect this material from exposure to light. Keep it away from oxidizing materials and store it at refrigerated temperatures. (NTP, 1992)

MINIMUM PROTECTIVE CLOTHING: If Tyvek-type disposable protective clothing is not worn during handling of this chemical, wear disposable Tyvek-type sleeves taped to your gloves. RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with a combination filter cartridge, i.e. organic vapor/acid gas/HEPA (specific for organic vapors, HCl, acid gas, SO2 and a high efficiency particulate filter). (NTP, 1992)

AMONG 4 FIBER DRUMS OF THIS CHEMICAL /N-HYDROXYMETHYLACRYLAMIDE/, 2 OF WHICH HAD NEVER BEEN OPENED, EXCESSIVE HEAT, SMOKE, CRACKLING & SMALL FLAME WERE NOTED. VERY SMALL AMOUNTS OF CONTAMINANT ARE BELIEVED TO HAVE CATALYZED THIS POLYMERIZATION REACTION, BUT STORAGE IN EXCESSIVELY HEATED AREAS CAN ALSO START THE REACTION.|May undergo spontaneous combustion in storage.

Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Do NOT let this chemical enter the environment. Sweep spilled substance into covered containers. Then store and dispose of according to local regulations.

Separated from acids. Store only if stabilized. Store in an area without drain or sewer access.

A harmful concentration of airborne particles can be reached quickly when dispersed, especially if powdered.

The substance is mildly irritating to the eyes and skin. The substance may cause effects on the nervous system.

The substance may have effects on the peripheral nervous system. Animal tests show that this substance possibly causes toxicity to human reproduction or development.

NO open flames.

AVOID ALL CONTACT! IN ALL CASES CONSULT A DOCTOR! IN ALL CASES CONSULT A DOCTOR!

Use local exhaust or breathing protection.

Protective gloves.

Wear safety goggles or eye protection in combination with breathing protection.

LD50 Rat oral 474 mg/kg|LD50 Rat ip 563 mg/kg|LD50 Mouse oral 420 mg/kg

... Toxicology and carcinogenesis studies were conducted by administering N-methylolacrylamide (98% pure) in water by gavage to groups of F344/N rats and B6C3Fl mice of each sex for ... 2 yr. ... Two yr studies were conducted by administering 0, 6, or 12 mg/kg N-methylolacrylamide in water by gavage, 5 days/wk for 103 wk, to groups of 50 rats of each sex. Groups of 50 mice of each sex were administered 0, 25, or 50 mg/kg on the same schedule. ... Conclusions: Under the conditions of these 2 year studies, there was no evidence of carcinogenic activity of N-methylolacrylamide for male or female F344/N rats receiving doses of 6 or 12 mg/kg/day by aqueous gavage. There was clear evidence of carcinogenic activity of N-methylolacrylamide for male B6C3Fl mice, based on increased incidences of neoplasms of the Harderian gland, liver, and lung. There was clear evidence of carcinogenic activity of N-methylolacrylamide for female B6C3Fl mice, based on increased incidences of neoplasms of the Harderian gland, liver, lung, and ovary.|N'(Hydroxymethyl)-acrylamide (HACR) was evaluated for reproductive toxicity, neurotoxicity, & dominant lethal effects using a modified Reproductive Assessment by Continuous Breeding (RACB) Protocol in CD-1 (Swiss) mice. ... During the continuous breeding phase, exposure to HACR at doses ranging from 11.1+/-0.57 mg/kg/day in the low-dose group males (60 ppm in water), to 113.4+/-15.86 mg/kg/day in the high-dose group females (360 ppm in water), for 27 wks of cohabitation, significantly affected measures of reproductive competence, including a 26% decr in the number of live pups/litter at 360 ppm & an increased inter-birth interval at all doses. However, the mean number of litters/pair, the proportion of pups born alive, or adjusted live pup weight were not affected. In a modified dominant lethal test. HACR-treated F0 males were mated to nontreated females. Significantly more early resorptions were detected at 180 ppm (/about/ 30-40 mg/kg/day) & higher, & fewer pups were born at 360 ppm (/about/ 80 mg/kg/day), indicating an effect of HACR on male reproduction. However, the crossover mating trial indicated no significant affect of 360 ppm HACR on any indices of fertility or mating & did not clearly indicate the affected sex, even though the number of pups/litter was reduced by 1.5 pups on the avg when sires were HACR treated (control x control, 10.6+/-1.0 vs. HACR male x control female, 9.1+/-0.9). Clinically, no dose-related signs were noted in F0 HACR- treated mice. F0 body weight & feed consumption during the initial weeks of HACR exposure were not adversely affected by treatment. HACR produced only slight changes in grip strength: in forelimbs of females after 12 wks (360 ppm) & 27 wks (180 & 360 ppm) of treatment. Trends towards reduced grip strength were also observed in the hind limbs of females & forelimbs of males after 12 wks of dosing. At necropsy of F0 adults, HACR (360 ppm) caused a 14% decr in testicular weight from controls, a 7% reduction in the total number of spermatids, & a 14% reduction in the concn of epididymal spermatozoa. No other dose-related trends in reproductive or somatic organ or body weights were noted for males & none for females. Estrual cycle characteristics were normal. No treatment-related reproductive, neural, or somatic organ histopathology was observed in either sex. In the second generation (F1) growth phase. HACR at dose levels of > or =60 ppm in water did not adversely affect preweaning growth or survival of the F1 generation. However, after weaning, dose-related decreases in body weight occurred in the face of increased water & feed consumption between 82+/-10 & 110+/-10 days of age in the F1 generation, more so in males than in females. Calculated exposure averaged between 15.6+/-0.61 & 188.8+/-11.3 mg/kg/day for adult F1 males & females at 60 & 360 ppm, respectively. No treatment related clinical signs were noted. In the F1 mating trial, HACR at > or =60 ppm had slight effects on the reproductive competence of the F1 generation. HACR caused a 18%-55% reduction in the number of live F2 pups/litter at > or =60 ppm & reduced dam weight by 5%-9% at > or =60 ppm. HACR clearly decreased forelimb & hind limb grip strength of males & hind limbs of females for Weeks 3-10 at most doses, with the forelimb of females being affected only at Week 10. There were significant treatment affects on male body weight, so that any decreases in reproductive organ weight when adjusted for body size were not significant. The exception was the seminal vesicles at 360 ppm, which were relatively smaller than for controls. Sperm parameters significantly affected by HACR were limited to the epididymal spermatozoa concns at 360 ppm (reduced by 13%): Spermatid counts (/mg of testicular weight) were non-significantly decreased (8%), & testicular histopathology was not markedly different from controls. In F1 females, terminal body weight was not reduced, & HACR had no affect on reproductive organ weight, vaginal cytology, or histopathology. In summary, exposure to HACR in water at dose levels as high as 360 ppm (/about/ 115 mg/kg/day), for up to 27 wks, resulted in moderate reproductive toxicity--decreased pups/litter at 360 ppm in F0 mice & at 60, 180, & 360 ppm in F1 mice, longer inter-litter interval in F0 females at 60, 180, & 360 ppm, & increased postimplantation loss (dominant lethal effect at 180 & 360 ppm) for untreated females mated to F0 males, in the absence of any clear-cut systemic toxicity in F0 mice. F1 mice had lowered body weights & increased liver & kidney/adrenal weight at all doses. Testicular toxicity was present in F0 animals at 360 ppm as indicated by decreased weight. Histopathology was not evident. F1 animals were more susceptible than F0 animals to the neuromuscular effects of HACR at all doses: HACR consistently decreased grip strength in both limbs of both sexes in F1 animals during post-weaning development, as opposed to sporadic effects in the hind limbs & forelimbs of F0 animals: more often in females. Neurotoxicity & litter effects were present in both F0 & F1 animals at doses lower than for currently or previously described testicular effects. The F1 generation, exposed from the time of gametogenesis, was more susceptible to neurotoxic & reproductive effects than were the F0 animals. We were not able to separate reproductive effects from testicular toxicity, although early resorptions occurred at a lower dose (180 ppm) than decreased testicular weight (360 ppm). Testicular effects were observed in F0 males at doses that did not cause neurotoxicity. Thus, these data indicate that HACR does affect reproductive performance of either F0 or F1 mice under the conditions used in Tasks 2-4 of this study (at doses < or =120 mg/kg/day). HACR had dominant lethal effects, which reduced live litter size by 26% in the F0 mice & by as much as 55% for the F1 mice at the high dose. The reduced number of pups/litter was equivalent in pairs fed HACR to those after exposed males were mated to nontreated females in the dominant lethal test. Thus, the dominant lethal effects may account for all of the F0 reproductive toxicity.

N-HYDROXYMETHYLACRYLAMIDE IV INJECTED INTO RATS @ 140 MG/KG WAS DISTRIBUTED THROUGHOUT THE TOTAL BODY WATER WITHIN A FEW MIN. BREAKDOWN OF N-HYDROXYMETHYLACRYLAMIDE TO ACRYLAMIDE WAS NEGLIGIBLE IN VITRO & IN VIVO. IT CAUSED A RAPID DECR IN LIVER GLUTATHIONE IN VIVO & GLUTATHIONE CONJUGATES WERE EXCRETED IN THE BILE.

IN VITRO BIOTRANSFORMATION OF ACRYLAMIDE & 10 RELATED CMPDS IN THE HEPATIC ENZYME SYSTEM OF THE MOUSE WERE STUDIED. ALL ANALOGS STUDIED WERE METABOLIZED BY HEPATIC GLUTATHIONE S-TRANSFERASE.

AFTER A DOSE OF 100 MG/KG OF ACRYLAMIDE NO NEUROLOGICAL SIGNS OF NEUROPATHY HAD YET APPEARED, BUT RETROGRADE BUILDUP OF PROTEIN LABEL WAS SIGNIFICANTLY REDUCED FOR THE LONG INTERVAL. TO TEST THE SPECIFICITY OF ACRYLAMIDE ON THE RETROGRADE TRANSPORT DEFECT N-HYROXYMETHYLACRYLAMIDE WAS STUDIED. IT DID NOT INFLUENCE THE TRANSPORT.

SYMPTOMS: Symptoms of exposure to this compound include irritation of the eyes, skin, mucous membranes and upper respiratory tract. Compounds of this class cause peripheral neuropathies, paresthesias, weakness in lower limbs and bluish, sweaty cold hands with erythema and peeling of the palms. ACUTE/CHRONIC HAZARDS: The vapor or mist of this compound is irritating to the skin, eyes, mucous membranes and upper respiratory tract. In aqueous solution, this compound is readily absorbed through the skin. When heated to decomposition it emits toxic fumes of carbon dioxide, carbon monoxide and nitrogen oxides. (NTP, 1992)

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop. SKIN: IMMEDIATELY flood affected skin with water while removing and isolating all contaminated clothing. Gently wash all affected skin areas thoroughly with soap and water. IMMEDIATELY call a hospital or poison control center even if no symptoms (such as redness or irritation) develop. IMMEDIATELY transport the victim to a hospital for treatment after washing the affected areas. INHALATION: IMMEDIATELY leave the contaminated area; take deep breaths of fresh air. IMMEDIATELY call a physician and be prepared to transport the victim to a hospital even if no symptoms (such as wheezing, coughing, shortness of breath, or burning in the mouth, throat, or chest) develop. Provide proper respiratory protection to rescuers entering an unknown atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA) should be used; if not available, use a level of protection greater than or equal to that advised under Protective Clothing. INGESTION: DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing, give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a hospital or poison control center. Be prepared to transport the victim to a hospital if advised by a physician. If the victim is convulsing or unconscious, do not give anything by mouth, ensure that the victim's airway is open and lay the victim on his/her side with the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport the victim to a hospital. OTHER: Since this chemical is a known or suspected carcinogen you should contact a physician for advice regarding the possible long term health effects and potential recommendation for medical monitoring. Recommendations from the physician will depend upon the specific compound, its chemical, physical and toxicity properties, the exposure level, length of exposure, and the route of exposure. (NTP, 1992)

Fresh air, rest.

Remove contaminated clothes. Rinse and then wash skin with water and soap.

First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist respirations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool. Activated charcoal is not effective ... . Do not attempt to neutralize because of exothermic reaction. Cover skin burns with dry, sterile dressings after decontamination ... . /Organic acids and related compounds/|Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in respiratory arrest. Early intubation, at the first sign of upper airway obstruction, may be necessary. Positive pressure ventilation techniques with a bag valve mask device may be beneficial. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Watch for signs of fluid overload. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Consider vasopressors if patient is hypotensive with a normal fluid volume. Watch for signs of fluid overload ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Organic acids and related compounds/

monomethylolacrylamide

The substance can be absorbed into the body by inhalation, through the skin and by ingestion.

Cough. Sore throat.

Redness.

Redness.

Adhesive manufacturing|2-Propenamide, N-(hydroxymethyl)-: ACTIVE